An AI-based, automated workflow for identification and scoring of invasive tumors in Ki-67 stained breast cancer specimens.

Authors

null

Bhavika Patel

Lanterne Dx, Boulder, CO

Bhavika Patel , Stephanie Allen , Sameer S. Talwalkar , Navi Mehra , Jeppe Thagaard , Thomas W. Ramsing , Agnete Overgaard , Jeni Caldara

Organizations

Lanterne Dx, Boulder, CO, Visiopharm, Westminster, CO

Research Funding

No funding received

Background: Understanding the rate of tumor cell growth in breast cancer specimens may be indicative of disease aggressiveness, a tumor characteristic which can be used to make an informed treatment decision. The nuclear protein Ki-67 is increased in cells as they prepare to divide or proliferate and is therefore widely used as a proliferation marker for tumor progression. This degree of tumor cell proliferation, or the proliferative index, is commonly detailed in pathology reports shared with the patient care team. Methods: In this study, we utilized the Ki-67 [K2] immunohistochemistry (IHC) assay to stain 10 breast cancer specimens. Stained slides were imaged using the AT2 scanner (Leica Biosystems, Buffalo Grove, IL) and analyzed using the Visiopharm Image Analysis platform. Results: Previous efforts to assess Ki-67 positivity utilizing image analysis have relied on the use of a secondary stain or manual effort by the pathologist to exclude non-invasive tumor regions. These antiquated methods are costly to the lab as they require additional materials or valuable pathologist time. Our novel image analysis approach utilizes artificial intelligence (AI) to automatically denote non-invasive verses invasive tumor regions, which can then be used to quantify the Ki-67 proliferative index. Conclusions: This valuable tool will allow for greater accuracy, cost-savings, and time efficiency when analyzing breast cancer samples compared to traditional methods.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Tissue-Based Biomarkers

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr e15108)

DOI

10.1200/JCO.2022.40.16_suppl.e15108

Abstract #

e15108

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Annual Meeting

AI-based HER2-low IHC scoring in breast cancer across multiple sites, clones, and scanners.

First Author: Patrick Frey

Abstract

2023 ASCO Genitourinary Cancers Symposium

The CONFIDENT-P trial: Clinical implementation of artificial intelligence assistance in prostate cancer pathology.

First Author: Rachel Flach